CE14 - Physiologie et physiopathologie

A new pathway for reducing liver lipotoxicity bridging non-alcoholic steatohepatitis and atherosclerosis in type 2 diabetes – DETOXING

Submission summary

Nonalcoholic fatty liver disease (NAFLD) is an increasing chronic liver pathology affecting around 25% of the general population in Western countries. NAFLD is a continuum of pathological states ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) which can progress to fibrosis, cirrhosis, end stage liver disease and liver transplantation. Prevalence of NASH is three times more elevated in patients with type 2 diabetes (T2D) and is an independent risk factor for cardiovascular diseases (CVD). Accumulation of lipotoxic lipids such as ceramides in the liver has been reported to play a major role in the development of NASH by promoting insulin resistance, endoplasmic reticulum and oxidative stress and apoptosis in hepatocytes. The capacity of liver to eliminate the excess of ceramides is critical for reducing hepatic lipotoxicity and for protection from NASH.
Our preliminary data lead us to propose that the export of ceramides to high-density lipoproteins (HDL) mediated by the membrane ATP-Binding Cassette G1 (ABCG1) transporter might attenuate hepatic lipotoxicity and reduce the onset of NASH and CVD.
To address this hypothesis, we will investigate the 1). In vitro impact of the cytotoxic ceramide removal by ABCG1 using human hepatocytes and precision-cut liver slices obtained from healthy or NASH livers, 2). In vivo impact of the liver ABCG1 / HDL axis on the development of NASH and atherosclerosis using a unique mouse model exhibiting a “humanized” lipoprotein profile and susceptible to atherosclerosis and 3). Contribution of the liver ABCG1/HDL axis in the liver-heart crosstalk in NASH patients thanks to cohorts of well phenotyped T2D and NAFLD patients. All the experimental tools and cohorts are already available.
This project will help to propose new therapeutic strategies to decrease lipotoxicity in the liver and to reduce both NASH and CVD development in T2D patients.

Project coordination

Wilfried LE GOFF (Sorbonne Université)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CRC CENTRE DE RECHERCHE DES CORDELIERS
UMR ICAN Sorbonne Université
INSERM - UMR 1151 Institut National de la Santé et de la Recherche Médicale

Help of the ANR 465,740 euros
Beginning and duration of the scientific project: December 2022 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter